Search results
Jump to navigation
Jump to search
Google site results
Loading...
Wiki results
Page title matches
- 0 members (0 subcategories, 0 files) - 11:42, 15 January 2021
Page text matches
- ...h an interest in clinical cytogenetics, molecular genetics and genomics in cancer. [[Contact us]] for more information.''' [[File:Circos.png|100px|link=Main_Page]] '''Cancer Genomes''' [[Hematologoic and Lymphoid]] | [[Solid Tumors]] | [[CNS]] | [[P7 KB (905 words) - 22:59, 20 November 2017
- == Genes == * Cancer Genes A10 KB (1,089 words) - 22:30, 20 November 2017
- ...h an interest in clinical cytogenetics, molecular genetics and genomics in cancer.''' ...ermission from the copyright holder, ©International Agency for Research on Cancer.''|alt=]]7 KB (1,032 words) - 10:43, 5 March 2024
- ==General Disease Overview / Description of Cancer Category== ...blastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged|B-ALL with t(v;11q23.3); KMT2A-Rearranged]]3 KB (412 words) - 12:36, 3 November 2023
- {{DISPLAYTITLE:Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged}} ==Cancer Category/Type==9 KB (1,384 words) - 16:30, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,372 words) - 12:36, 3 November 2023
- == Genes Involved == ...t and t(14;19)(q32;q13) in lymphoproliferative disorders. Genes Chromosome Cancer 15:38–47CrossRef4 KB (537 words) - 21:44, 20 July 2016
- ==General Disease Overview / Description of Cancer Category== *[[B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged]]3 KB (349 words) - 12:37, 3 November 2023
- "KIT Proto-Oncogene Receptor Tyrosine Kinase"; "V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog"; PBT; "Stem C ==Cancer Category/Type==7 KB (1,047 words) - 14:32, 12 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,310 words) - 12:49, 3 November 2023
- ==General Disease Overview / Description of Cancer Category== ...5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B-ALL with t(v;11q23.3); KMT2A-Rearranged]]3 KB (430 words) - 16:30, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,358 words) - 16:40, 4 December 2023
- ...page can be found at [[HAEM4:Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged]]. ==Cancer Category / Type==19 KB (2,659 words) - 14:32, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,431 words) - 12:56, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,475 words) - 13:59, 3 November 2023
- .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)23 KB (3,285 words) - 15:49, 13 September 2019
- .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)23 KB (3,285 words) - 16:56, 8 August 2020
- .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)23 KB (3,282 words) - 11:49, 14 June 2019
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,397 words) - 12:33, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,774 words) - 12:56, 3 November 2023
- ...>Diaz JI, Mora LB, Hakam A. The Mainz Classification of Renal Cell Tumors. Cancer Control. 1999 Nov;6(6):571-579</ref> ...ton CJ. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 8;26(3):319-30.</ref>3 KB (421 words) - 11:29, 22 August 2016
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==11 KB (1,435 words) - 13:46, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,816 words) - 14:00, 3 November 2023
- ...Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics. |'''Genes'''17 KB (2,298 words) - 16:42, 22 April 2021
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,669 words) - 12:40, 3 November 2023
- ==Cancer Category/Type== ...scular endothelial growth factor (''VEGF'') (Merdzhanova et al., 2010). In cancer, ''SRSF2'' variants have been implicated in leukemia and myeloid disorders16 KB (2,281 words) - 14:50, 12 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,320 words) - 12:39, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,705 words) - 12:38, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,340 words) - 12:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,711 words) - 16:34, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,721 words) - 13:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,265 words) - 12:54, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,380 words) - 16:33, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,383 words) - 16:39, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,304 words) - 16:43, 4 December 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==6 KB (814 words) - 12:53, 3 November 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==6 KB (814 words) - 12:53, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (2,044 words) - 10:09, 27 February 2024
- Thank you for volunteering to help curate the Compendium of Cancer Genome Aberrations (CCGA)! Your help will make this resource a valuable to ...“Disease pages”. The CCGA is especially interested in the curation fusion genes/mutations that arise in disease, esp. in the hematological cancers. Howeve7 KB (1,171 words) - 17:30, 23 April 2019
- ...ed from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics. ...urvival in a cohort of MDS or AML patients treated with azacitidine. Blood Cancer J 2013;3:e155.[https://www.ncbi.nlm.nih.gov/pubmed/24185502]</ref><ref name38 KB (5,270 words) - 17:10, 30 April 2020
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,651 words) - 14:40, 13 December 2023
- ==Cancer Category/Type== Breast Cancer / Epithelial Tumours of the Breast19 KB (2,737 words) - 13:17, 29 February 2024
- {{DISPLAYTITLE:B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged}} ==Cancer Category/Type==6 KB (910 words) - 13:48, 3 November 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==13 KB (1,772 words) - 12:52, 3 November 2023
- ==Cancer Category/Type== ...ET2 and WT1 physically interact, suggesting overlapping pathways for these genes in AML (Wang et al., 2015). ''TET2'' mutations increase the response of low26 KB (3,824 words) - 15:01, 12 December 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==13 KB (1,811 words) - 13:58, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,693 words) - 12:30, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==6 KB (851 words) - 12:46, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,734 words) - 13:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (2,022 words) - 12:31, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==15 KB (2,002 words) - 12:34, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==23 KB (3,226 words) - 12:31, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==15 KB (1,965 words) - 14:30, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,766 words) - 12:38, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==7 KB (889 words) - 11:39, 14 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==23 KB (3,259 words) - 13:43, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,803 words) - 16:32, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==7 KB (1,040 words) - 12:57, 3 November 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category / Type==15 KB (2,067 words) - 14:23, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (2,056 words) - 13:43, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==7 KB (947 words) - 12:55, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (1,946 words) - 16:28, 4 December 2023
- ==Cancer Category/Type== ===Role in Cancer===20 KB (2,904 words) - 03:02, 13 August 2018
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==8 KB (1,082 words) - 14:00, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==7 KB (986 words) - 16:43, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==21 KB (2,882 words) - 12:37, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==21 KB (2,915 words) - 13:48, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,643 words) - 13:51, 25 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==31 KB (4,325 words) - 13:55, 25 February 2024
- ==General Disease Overview / Description of Cancer Category== ...|first2=Marry M.|last3=Aalbers|first3=Anna M.|last4=Balgobind|first4=Brian V.|last5=Hollink|first5=Iris H. I. M.|last6=Meijerink|first6=Jules P. P.|last7 KB (1,048 words) - 12:35, 3 November 2023
- ==General Disease Overview / Description of Cancer Category== ...|first2=Marry M.|last3=Aalbers|first3=Anna M.|last4=Balgobind|first4=Brian V.|last5=Hollink|first5=Iris H. I. M.|last6=Meijerink|first6=Jules P. P.|last7 KB (1,048 words) - 16:29, 4 December 2023
- ...&t=1s <u>A Resource for our Clinical Genomics Community: the Compendium of Cancer Genome Aberrations (CCGA) - YouTube</u>]''' ''iv) Research/experience in disease/genes of interest''10 KB (1,712 words) - 14:21, 12 December 2023
- ==Cancer Category/Type== ...tyrosine kinase receptor gene FGFR1, located in 8p11, and several partner genes, including ZMYM2 (wang et al).10 KB (1,469 words) - 17:05, 11 October 2018
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==34 KB (4,782 words) - 16:37, 20 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==8 KB (1,127 words) - 12:36, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==20 KB (2,747 words) - 14:28, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==25 KB (3,503 words) - 14:24, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,194 words) - 12:29, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==8 KB (1,169 words) - 16:30, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,392 words) - 12:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,537 words) - 12:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,239 words) - 13:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,586 words) - 16:35, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,440 words) - 16:35, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==40 KB (5,557 words) - 12:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,317 words) - 12:28, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==40 KB (5,593 words) - 16:34, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,334 words) - 12:32, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,360 words) - 11:38, 14 November 2023
- Hui Chen, MD, PhD, The University of Texas MD Anderson Cancer Center ==Cancer Category/Type==9 KB (1,336 words) - 16:42, 16 April 2024
- Cancer Metastasis Rev (2014) 33:1109–1124 PMID:[http://www.ncbi.nlm.nih.gov/pubm ...gnature PI3K/AKT and mTOR pathways elevated; high expression of several genes representing targets for immunotherapy including PDCD1, CD247, PDCD1LG2, CT8 KB (1,050 words) - 16:48, 19 August 2016
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,881 words) - 12:33, 3 November 2023
- ...yrosine kinase; Abelson tyrosine-protein kinase 1; ABL; JTK7; p150; c-ABL; v-abl; CHDSKM; c-ABL1; bcr/abl ==Cancer Category/Type==12 KB (1,695 words) - 13:43, 12 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,910 words) - 16:27, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,337 words) - 13:45, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==21 KB (2,936 words) - 14:33, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==11 KB (1,531 words) - 12:34, 3 November 2023
- ...Table derived from Chun et al., 2018 [PMID 30554732] with permission from Cancer Genetics. |'''Relevant Genes'''40 KB (5,707 words) - 22:25, 7 November 2020
- ...inal page can be found at [[HAEM4:B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged]]. ==Cancer Category / Type==12 KB (1,796 words) - 14:21, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,077 words) - 14:26, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==30 KB (4,118 words) - 14:20, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,215 words) - 12:42, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,152 words) - 14:16, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,330 words) - 12:36, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,257 words) - 16:35, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==11 KB (1,525 words) - 16:28, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,371 words) - 13:48, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==48 KB (6,794 words) - 14:27, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,066 words) - 12:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,750 words) - 12:32, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,108 words) - 16:39, 4 December 2023
- ==Cancer Category/Type== '''Breast Cancer'''36 KB (5,335 words) - 14:18, 12 December 2023
- |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center |Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia61 KB (7,864 words) - 16:23, 16 April 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,586 words) - 12:34, 3 November 2023
- ==Cancer Category/Type== Colorectal cancer13 KB (1,790 words) - 18:29, 5 January 2019
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,626 words) - 16:28, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,782 words) - 12:32, 3 November 2023
- UT MD Anderson Cancer Center ==Cancer Category/Type==12 KB (1,654 words) - 12:27, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,603 words) - 12:27, 3 November 2023
- ::Mismatch repair cancer syndrome :Familial non-medullary thyroid cancer38 KB (3,868 words) - 13:56, 12 December 2023
- ...L. Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics.'' See [[AML Table: Recurrent Genomic Alterations Detected by Chro ==General Disease Overview Description of Cancer Category==12 KB (1,728 words) - 12:31, 3 November 2023
- ==Cancer Category/Type== ...e [5]. Both hypo- and hypermethylation may be pathogenic in the context of cancer. Global hypomethylation may be associated with genomic instability. The ami14 KB (1,939 words) - 18:10, 5 January 2019
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,744 words) - 13:44, 3 November 2023
- UT MD Anderson Cancer Center ==Cancer Category/Type==12 KB (1,692 words) - 13:40, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,642 words) - 13:40, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,487 words) - 12:28, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==14 KB (1,883 words) - 14:30, 13 December 2023
- ...Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics. ...ehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer|url=https://pubmed.ncbi.nlm.nih.gov/23083876|journal=The Journal of Urology42 KB (5,820 words) - 13:40, 19 May 2021
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==14 KB (1,944 words) - 14:29, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,528 words) - 13:41, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==27 KB (3,643 words) - 14:36, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,772 words) - 13:44, 3 November 2023
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category/Type==32 KB (4,668 words) - 12:44, 3 November 2023
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category/Type==32 KB (4,712 words) - 16:36, 4 December 2023
- ...able derived from Akkari et al., 2020 [PMID 32302940] with permission from Cancer Genetics. All percentages are approximate. |[[KMT2A Partner Genes|KMT2A]] (11q23) rearrangements*33 KB (4,848 words) - 10:50, 26 July 2021
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (1,921 words) - 12:29, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==31 KB (4,428 words) - 12:28, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,599 words) - 12:27, 3 November 2023
- ==Cancer Category== ==Cancer Sub-Classification / Subtype==12 KB (1,663 words) - 12:47, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==32 KB (4,469 words) - 13:41, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==16 KB (2,198 words) - 12:37, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,637 words) - 13:40, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (1,967 words) - 16:23, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==17 KB (2,372 words) - 14:31, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,231 words) - 13:48, 3 November 2023
- ==Cancer Category== ==Cancer Sub-Classification / Subtype==12 KB (1,707 words) - 16:38, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,668 words) - 12:50, 3 November 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==30 KB (4,094 words) - 12:53, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,721 words) - 16:40, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==31 KB (4,371 words) - 14:25, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==18 KB (2,549 words) - 14:33, 13 December 2023
- Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category/Type==31 KB (4,151 words) - 16:42, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,443 words) - 12:30, 3 November 2023
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category / Type==41 KB (5,923 words) - 14:31, 13 December 2023
- Victorian Cancer Cytogenetics Service ==Cancer Category/Type==18 KB (2,595 words) - 12:29, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==18 KB (2,546 words) - 14:17, 13 December 2023
- ..., MS, Neuropathology Fellow Houston Methodist/Texas Children’s/MD Anderson Cancer Center ==Cancer Category/Type==36 KB (5,058 words) - 13:49, 25 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,487 words) - 16:24, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,651 words) - 14:36, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,721 words) - 14:32, 13 December 2023
- Victorian Cancer Cytogenetics Service ==Cancer Category/Type==19 KB (2,643 words) - 16:23, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,652 words) - 14:34, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,330 words) - 12:30, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==31 KB (4,295 words) - 14:22, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,424 words) - 12:57, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==34 KB (4,742 words) - 14:34, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,371 words) - 13:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,578 words) - 12:33, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,350 words) - 13:52, 25 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,470 words) - 14:00, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,722 words) - 14:16, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==16 KB (2,213 words) - 12:30, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,576 words) - 13:45, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==34 KB (4,834 words) - 14:25, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==16 KB (2,255 words) - 13:42, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,751 words) - 14:31, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==40 KB (5,552 words) - 14:34, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,410 words) - 12:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==33 KB (4,667 words) - 12:50, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==33 KB (4,705 words) - 16:40, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==21 KB (2,953 words) - 14:17, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,476 words) - 16:34, 4 December 2023
- UT MD Anderson Cancer Center ==Cancer Category / Type==21 KB (2,945 words) - 14:37, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==21 KB (2,920 words) - 14:35, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,522 words) - 12:33, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==23 KB (3,154 words) - 14:37, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,208 words) - 12:30, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==21 KB (2,981 words) - 14:18, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==16 KB (2,315 words) - 12:39, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,561 words) - 16:27, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==54 KB (7,733 words) - 12:52, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==55 KB (7,774 words) - 16:41, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,250 words) - 16:24, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==39 KB (5,484 words) - 14:43, 20 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,367 words) - 16:33, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==24 KB (3,252 words) - 14:20, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,670 words) - 12:38, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,037 words) - 14:41, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,686 words) - 13:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,046 words) - 12:33, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,362 words) - 12:53, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,074 words) - 13:28, 29 February 2024
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,137 words) - 10:13, 27 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,401 words) - 13:58, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==24 KB (3,323 words) - 14:33, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,071 words) - 13:45, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==23 KB (3,346 words) - 12:52, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==42 KB (5,916 words) - 14:32, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==24 KB (3,388 words) - 16:41, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==64 KB (9,095 words) - 14:16, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==23 KB (3,102 words) - 13:55, 25 February 2024
- Victorian Cancer Cytogenetics Service ==Cancer Category / Type==28 KB (3,984 words) - 14:32, 13 December 2023
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category/Type==73 KB (10,415 words) - 12:41, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==27 KB (3,639 words) - 14:37, 13 December 2023
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category/Type==73 KB (10,453 words) - 13:51, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==26 KB (3,785 words) - 14:16, 13 December 2023
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category / Type==80 KB (11,414 words) - 14:36, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==26 KB (3,699 words) - 14:26, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==26 KB (3,527 words) - 14:25, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==24 KB (3,384 words) - 12:52, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==27 KB (3,735 words) - 14:32, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==24 KB (3,423 words) - 16:42, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==24 KB (3,493 words) - 12:46, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==27 KB (3,873 words) - 12:32, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==24 KB (3,499 words) - 16:37, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==27 KB (3,828 words) - 14:18, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==27 KB (3,880 words) - 13:44, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==28 KB (3,970 words) - 14:19, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==31 KB (4,299 words) - 14:17, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==32 KB (4,584 words) - 14:16, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==30 KB (4,324 words) - 14:16, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==33 KB (4,726 words) - 14:22, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==33 KB (4,821 words) - 12:54, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==33 KB (4,858 words) - 13:58, 3 November 2023
- ...somal abnormalities identified by standard methods has led to discovery of genes, and gene function and dysfunction. This knowledge has led to improved ther ..., et al.; Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult59 KB (8,449 words) - 19:11, 27 July 2016
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==42 KB (6,120 words) - 14:27, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==47 KB (6,652 words) - 12:47, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==47 KB (6,699 words) - 16:38, 4 December 2023
- ...://pubmed.ncbi.nlm.nih.gov/32203924/ PMID: 32203924]] with permission from Cancer Genetics. ...ilocytic astrocytomas|url=https://pubmed.ncbi.nlm.nih.gov/18974108|journal=Cancer Research|volume=68|issue=21|pages=8673–8677|doi=10.1158/0008-5472.CAN-08-103 KB (13,991 words) - 17:05, 20 April 2021
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==56 KB (7,988 words) - 14:24, 13 December 2023